循环肿瘤DNA在肾癌中的研究进展

doi:10.11904/j.issn.1002-3070.2021.05.011

Abstract

Abstract: Liquid biopsy technology based on circulating tumor cells(CTCs)and free nucleic acids has a potential application value in the whole process from malignant tumor diagnosis to follow-up.Compared with traditional tissue biopsy,the advantages of circulating tumor DNA(ctDNA)testing is that it has low risk,can be continuously tested,and can monitor the recurrence of the disease and the response to treatment over time.The sensitivity of ctDNA detection depends on the detection technology and genetic platform used,and is also affected by tumor location,staging,tumor heterogeneity,and tumor clonality.ctDNA has also been well applied in the treatment selection of renal cell carcinoma(RCC),drug resistance monitoring,and prediction of response to everolimus treatment.This article mainly reviews the current research status and challenges of ctDNA in renal cancer.

Key words: Renal cell carcinoma, Circulating tumor DNA, Circulating tumor cells, Liquid biopsy

CLC Number:

R737.1

ZHANG Lu, DONG Zhenkun, CUI Yan. Research progress of circulating tumor DNA in renal cancer[J]. Journal of Practical Oncology, 2021, 35(5): 447-451.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.05.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I5/447

References

1 Bergerot PG,Hahn AW,Bergerot CD,et al.The role of circulating tumor DNA in renal cell carcinoma[J].Curr Treat Options Oncol,2018,19(2):10.
2 Siegel RL,Miller KD,Jemal A.Cancer statistics,2019[J].CA Cancer J Clin,2019,69(1):7-34.
3 Nassar AH,Hamieh L,Gray KP,et al.Mutations and response to rapalogs in patients with metastatic renal cell carcinoma[J].Mol Cancer Ther,2020,19(2):690-696.
4 Voss MH,Chen D,Reising A,et al.PTEN expression,not mutation status in TSC1,TSC2,or mTOR,correlates with the outcome on everolimus in patients with renal cell carcinoma treated on the randomized RECORD-3 Trial[J].Clin Cancer Res,2019,25(2):506-514.
5 Hsieh JJ,Chen D,Wang PI,et al.Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma[J].Eur Urol,2017,71(3):405-414.
6 Yang Y,Miller CR,Lopez-Beltran A,et al.Liquid biopsies in the management of bladder cancer:next-generation biomarkers for diagnosis,surveillance,and treatment-response prediction[J].Crit Rev Oncog,2017,22(5-6):389-401.
7 Chen X,Wang L,Lou J.Nanotechnology strategies for the analysis of circulating tumor DNA:a review[J].Med Sci Monit,2020,26:e921040.
8 Wan J,Zhu L,Jiang Z,et al.Monitoring of plasma cell-free DNA in predicting postoperative recurrence of clear cell renal cell carcinoma[J].Urol Int,2013,91(3):273-278.
9 Bettegowda C,Sausen M,Leary RJ,et al.Detection of circulating tumor DNA in early-and late-stage human malignancies[J].Sci Transl Med,2014,6(224):224ra24.
10 Cheng F,Su L,Qian C.Circulating tumor DNA:a promising biomarker in the liquid biopsy of cancer[J].Oncotarget,2016,7(30):48832-48841.
11 Hahn AW,Gill DM,Maughan B,et al.Correlation of genomic alterations assessed by next-generation sequencing(NGS)of tumor tissue DNA and circulating tumor DNA(ctDNA)in metastatic renal cell carcinoma(mRCC):potential clinical implications[J].Oncotarget,2017,8(20):33614-33620.
12 Chae YK,Davis AA,Carneiro BA,et al.Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA[J].Oncotarget,2016,7(40):65364-65373.
13 Al-Qassab U,Lorentz CA,Laganosky D,et al.Pnfba-12 liquid biopsy for renal cell carcinoma[J].J Urol,2017,197(4):913-914.
14 Pal SK,Sonpavde G,Agarwal N,et al.Evolution of circulating tumor DNA profile from first-line to subsequent therapy in metastatic renal cell carcinoma[J].Eur Urol,2017,72(4):557-564.
15 Cimadamore A,Gasparrini S,Massari F,et al.Emerging molecular technologies in renal cell carcinoma:liquid biopsy[J].Cancers(Basel),2019,11(2):196.
16 Rhoades Smith KE,Bilen MA.A review of papillary renal cell carcinoma and MET inhibitors[J].Kidney Cancer,2019,3(3):151-161.
17 Voss MH,Hakimi AA,Pham CG,et al.Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy[J].Clin Cancer Res,2014,20(7):1955-1964.
18 Hauser S,Zahalka T,Fechner G,et al.Serum DNA hypermethylation in patients with kidney cancer:results of a prospective study[J].Anticancer Res,2013,33(10):4651-4656.
19 Jung M,Ellinger J,Gevensleben H,et al.Cell-Free SHOX2 DNA Methylation in blood as a molecular staging parameter for risk stratification in renal cell Carcinoma Patients:A Prospective Observational Cohort Study[J].Clin Chem,2019,65(4):559-568.
20 李恒震,张艳桥.液体活检在结直肠癌诊断中的应用进展[J].实用肿瘤学杂志,2020,34(4):357-361.
21 Rodrigues Filho EM,Simon D,Ikuta N,et al.Elevated cell-free plasma DNA level as an independent predictor of mortality in patients with severe traumatic brain injury[J].J Neurotrauma,2014,31(19):1639-1646.
22 Shimony A,Zahger D,Gilutz H,et al.Cell free DNA detected by a novel method in acute ST-elevation myocardial infarction patients[J].Acute Card Care,2010,12(3):109-111.
23 Clementi A,Virzì GM,Brocca A,et al.The role of Cell-Free plasma DNA in critically Ill patients with sepsis[J].Blood Purif,2016,41(1-3):34-40.
24 Feng G,Ye X,Fang F,et al.Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma[J].Dis Markers,2013,34(2):105-111.
25 Yamamoto Y,Uemura M,Fujita M,et al.Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma[J].Cancer Sci,2019,110(2):617-628.
26 Shen SY,Singhania R,Fehringer G,et al.Sensitive tumour detection and classification using plasma cell-free DNA methylomes[J].Nature,2018,563(7732):579-583.
27 Dunaeva M,Pruijn GJM.Global characterization of circulating nucleic acids[J].Methods Mol Biol,2020,2063:257-268.
28 Piva F,Giulietti M,Santoni M,et al.Epithelial to mesenchymal transition in renal cell carcinoma:implications for cancer therapy[J].Mol Diagn Ther,2016,20(2):111-117.
29 Nel I,Gauler TC,Bublitz K,et al.Circulating tumor cell composition in renal cell carcinoma[J].PLoS One,2016,11(4):e0153018.
30 Liu S,Tian Z,Zhang L,et al.Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients[J].Oncotarget,2016,7(37):59877-59891.
31 Oellerich M,Schütz E,Beck J,et al.Circulating Cell-Free DNA-Diagnostic and prognostic applications in personalized cancer therapy[J].Ther Drug Monit,2019,41(2):115-120.
32 Mader S,Pantel K.Liquid biopsy:current status and future perspectives[J].Oncol Res Treat,2017,40(7-8):404-408.

[1]	HAN Jing, PU Yan, LIU Huibin. Effects of SKA1 on cell proliferation and apoptosis of renal cell carcinoma and its molecular mechanism [J]. Journal of Practical Oncology, 2020, 34(5): 404-411.
[2]	LI Hengzhen, ZHANG Yanqiao. Application progress of liquid biopsy in the diagnosis of colorectal cancer [J]. Journal of Practical Oncology, 2020, 34(4): 357-361.
[3]	HAN Xueyang, LI Bin, SUN Zhaoyong, WANG Fangming, LIU Yong. Effect of perioperative infection on tumor-specific survival after nephrectomy for renal cell carcinoma [J]. Journal of Practical Oncology, 2020, 34(2): 169-175.
[4]	YAN Ruodong, REN Shan, SUI Wenyin, PIAO Renjing. Expression and mechanism of TMEM45A in renal clear cell carcinoma [J]. Journal of Practical Oncology, 2019, 33(4): 317-322.
[5]	CUI Xueyang,XING Chengzhong. The research and application of liquid biopsy in the field of colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 367-370.
[6]	XU Xunzheng, ZHANG Haogang, QIAO Pengfei, WANG Fujing. Clinical efficacy and practicability analysis of circulating tumor cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 169-173.
[7]	LUO Bin ,SHI Qihui ,LIU Jiaxiang ,TIAN Jianhui. The clinical significance of circulating tumor cells in lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(4): 370-374.
[8]	CAI Li, SONG Xiaowei, PAN Lihua, SHI Guangyue, LIU Wei, SUN Lichun, CHEN Xuesong, ZHAO Lina. The significance of epithelial mesenchymal transitions gene Twist in circulating tumor cells to efficacy of chemotherapy in metastatic breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2013, 27(1): 37-41.
[9]	TANG Dabei,ZHANG Qingyuan,WANG Jingxuan,ZHAO Shu,ZHAO Wenhui. A clinical study of estradiol therapy in endocrine-resistant advanced breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(4): 289-292.
[10]	QIAN Liuqi,LIU Qian,LIU Yi,ZHANG Shaohua,WANG Tao,WU Shikai,SONG Santai,LIU Bing,JIANG Zefei. Expression of circulating tumor cells in metastatic breast cancer patients and its relationship with multiple serum tumor markers [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(3): 220-224.

Research progress of circulating tumor DNA in renal cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 10

Recommended Articles

Metrics

Comments